Search filters

Filters

Clear All

Phase

  • 6
  • 1
  • 2
  • 1
  • 3
  • 14
  • 6
  • 14
  • 14

Found 14 Soft Tissue Sarcoma trials

A listing of Soft Tissue Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study to Evaluate the Safety of Trabectedin Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

A Study to Evaluate the Safety of Trabectedin Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

10 years - 99 years
All genders
Phase 1
Interventional
This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Learn More
PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

18 years - 99 years
All genders
Phase 1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
Learn More

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

All genders
Phase 1/2
Interventional
The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat …
Learn More

CART-38 in Adult AML and MM Patients - 1

All genders
Phase 1
Interventional
Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can …
Learn More
11 - 14 of 14